Published in Front Pharmacol on September 08, 2015
Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol (2016) 0.78
Salvinorin A Inhibits Airway Hyperreactivity Induced by Ovalbumin Sensitization. Front Pharmacol (2017) 0.75
Highly Potent and Selective New Diphenethylamines Interacting with the κ-Opioid Receptor: Synthesis, Pharmacology, and Structure-Activity Relationships. J Med Chem (2017) 0.75
The mesolimbic dopamine reward circuit in depression. Biol Psychiatry (2006) 7.62
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34
Psychotomimesis mediated by kappa opiate receptors. Science (1986) 3.60
Anatomy of CNS opioid receptors. Trends Neurosci (1988) 2.82
Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther (2005) 2.66
The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res (2009) 2.61
Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) (2005) 2.60
Specific receptor for the opioid peptide dynorphin: structure--activity relationships. Proc Natl Acad Sci U S A (1981) 2.53
International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev (1996) 2.43
Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther (1988) 2.29
Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol (1994) 2.28
Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther (2004) 1.97
Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) (2010) 1.90
The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem (1990) 1.71
Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). J Ethnopharmacol (1983) 1.49
Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) (2005) 1.43
Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther (2001) 1.41
Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology (2005) 1.34
'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Res Mol Brain Res (1993) 1.32
κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci (2012) 1.29
Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport (1994) 1.28
kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A (1995) 1.26
The dynorphin/κ-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci (2011) 1.25
Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. J Pharmacol Exp Ther (1998) 1.24
Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage (2008) 1.23
2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A. J Pharmacol Exp Ther (2007) 1.22
Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) (2004) 1.21
Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend (2010) 1.20
The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) (2003) 1.17
Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem (2013) 1.17
Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neuroreport (1993) 1.15
Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res (2001) 1.15
Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther (2008) 1.12
Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther (2006) 1.12
Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend (2010) 1.12
The therapeutic potential of κ-opioids for treatment of pain and addiction. Neuropsychopharmacology (2011) 1.11
Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol (2005) 1.10
Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol (2007) 1.09
Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry (2007) 1.09
Adolescent salvia substance abuse. Addiction (2007) 1.07
Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg Med Chem Lett (2001) 1.06
The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther (2014) 1.05
Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry (2012) 1.04
κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake. J Neurosci (2015) 1.03
Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats. J Pharmacol Exp Ther (2011) 1.03
Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology (Berl) (2008) 1.03
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg Med Chem Lett (2011) 1.03
The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol (1997) 1.00
Identification of novel functionally selective κ-opioid receptor scaffolds. Mol Pharmacol (2013) 1.00
Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacology (Berl) (2009) 1.00
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology (2013) 0.99
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl) (2012) 0.97
Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys. J Pharmacol Exp Ther (2007) 0.97
Persistent psychosis associated with salvia divinorum use. Am J Psychiatry (2009) 0.96
Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther (1999) 0.95
Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil (2011) 0.94
Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther (1986) 0.93
College student use of Salvia divinorum. Drug Alcohol Depend (2008) 0.92
Distinct effects of methamphetamine and cocaine on preprodynorphin messenger RNA in rat striatal patch and matrix. J Neurochem (2003) 0.92
Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol (2004) 0.92
Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans. AAPS J (2011) 0.91
Dynorphin--still an extraordinarily potent opioid peptide. Mol Pharmacol (2012) 0.91
Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology (Berl) (2011) 0.91
Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo. J Pharmacol Exp Ther (2012) 0.90
Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Clin Neuropharmacol (1996) 0.90
Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl) (2007) 0.90
Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. Br J Pharmacol (2014) 0.89
Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology (2008) 0.89
Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology (2014) 0.88
The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmacology (Berl) (2010) 0.87
Involvement of dynorphin and kappa opioid receptor in yohimbine-induced reinstatement of heroin seeking in rats. Synapse (2013) 0.86
The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior. J Nat Prod (2013) 0.86
Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues. J Med Chem (2014) 0.85
Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic kappa-opioid agonists in rhesus monkeys. Psychoneuroendocrinology (2004) 0.85
Neoclerodanes as atypical opioid receptor ligands. J Med Chem (2013) 0.85
Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur J Pharmacol (1999) 0.83
Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. Brain Res Mol Brain Res (1999) 0.83
Use of Salvia divinorum in a nationally representative sample. Am J Drug Alcohol Abuse (2011) 0.82
Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias. ACS Chem Neurosci (2015) 0.81
Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence. Adv Pharmacol (2014) 0.80
Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacology (Berl) (2010) 0.80
Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats. Pharmacol Biochem Behav (2010) 0.79
Chromatin alterations in response to forced swimming underlie increased prodynorphin transcription. Neuroscience (2012) 0.78
Virus-mediated shRNA knockdown of prodynorphin in the rat nucleus accumbens attenuates depression-like behavior and cocaine locomotor sensitization. PLoS One (2014) 0.78
Ontogeny of mu- and kappa-opiate receptor control of the hypothalamo-pituitary-adrenal axis in rats. Endocrinology (1991) 0.78
Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat. Psychopharmacology (Berl) (2014) 0.77